Caplin Steriles enters into a strategic partnership with Jamp Pharma Group for Canada

Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) announced that Caplin Steriles Limited (a Subsidiary of Caplin Point Laboratories Ltd) has entered into a strategic partnership with JAMP Pharma Group for six injectable products to be filed shortly in Canada. Some of these products have already been filed by Caplin Steriles in the USA.

Commenting on the transaction, Mr C. C. Paarthipan, Chairman of Caplin Point Laboratories Limited, said: "We have targeted Canada as one of our key expansion areas in Regulated Markets and we are excited to work with JAMP, one of the fastest growing companies in Canada. We are confident that we will be adding more products to this partnership in due course."

Louis Pilon, JAMP Pharma Group's CEO added "We are very pleased and excited to enter into this partnership with Caplin Point Laboratories Limited. This partnership will allow us to continue our mission to provide more affordable options to Canadian patients, as well as our retail and institutional partners. We certainly hope to collaborate on more products with our new partner in the coming years."

Shares of CAPLIN POINT LABORATORIES LTD. was last trading in BSE at Rs.488.3 as compared to the previous close of Rs. 491.65. The total number of shares traded during the day was 5851 in over 376 trades.

The stock hit an intraday high of Rs. 496 and intraday low of 486.05. The net turnover during the day was Rs. 2874705.

Source : Equity Bulls

Keywords